Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer

30 Mar 2006

Abstract excerpt

Overexpression of the polycomb group protein enhancer of zeste homologue 2 (EZH2) has been found in several malignancies, including prostate cancer, with an aggressive phenotype. Amplification of the gene has previously been demonstrated in several malignancies, but not in prostate cancer. Our goal was to evaluate the gene copy number and expression alterations of EZH2 in prostate cancer. The copy number of EZH2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16575874
DOI: 10.1002/gcc.20327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancerPMID 16575874Read ↗

The polycomb group protein EZH2 is involved in progression of prostate cancer.Semantic proximity Read ↗

Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.Semantic proximity Read ↗

Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancerSemantic proximity Read ↗

Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell LineSemantic proximity Read ↗

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersSemantic proximity Read ↗

Mutations and deletions of PRC2 in prostate cancer.Semantic proximity Read ↗

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesSemantic proximity Read ↗

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.Semantic proximity Read ↗

Androgens Suppress EZH2 Expression Via Retinoblastoma (RB) and p130-Dependent Pathways: A Potential Mechanism of Androgen-Refractory Progression of Prostate CancerSemantic proximity Read ↗

Polycomb-mediated silencing in neuroendocrine prostate cancerSemantic proximity Read ↗

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsSemantic proximity Read ↗

Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.